

Advanced Personalised Therapeutics in Gynaecological Cancers

St Hugh's College, Oxford | 21st February 2020

Registration is free. To register use this link

<https://forms.gle/T9ZKFF7Txctw1HYA>

Recent technological advances in genomics, computational biology and immunology have made individualised therapies for cancer patients a reality. Moreover, exciting developments in cell and gene therapy have made the translation of such individualised discoveries to personalised advanced therapeutic medicinal products (ATMPs) possible. This era of novel individualised therapeutics challenges the traditional standards of therapeutic intervention and provides real opportunities for a paradigm shift in our approach to cancer therapy. This symposium brings together some of the world leaders in genomics, computational biology, immunology and ATMPs to discuss the state-of-the-art with a focus on gynaecological cancers. We hope that the symposium will provide a forum for discussion of future directions in this field.

Scientific Committee



Professor Ahmed Ashour Ahmed
Cancer Genomics,
Immunology and Cell Biology



Dr David Church
Cancer Genomics and
Immunology



Dr David Wedge
Cancer Genomics and
Computational Biology



Confirmed Speakers

Dr James Brenton

Senior Group Leader, Cancer Research UK Cambridge Institute, Honorary Consultant in Medical Oncology, Addenbrooke's Hospital, Cambridge University Hospitals

Professor Peter Campbell

Head of Cancer, Ageing and Somatic Mutation, and Senior Group Leader, Sanger Institute

Dr Stuart Curbishley

Head of Business and Project Development, Advanced Therapies, University of Birmingham

Professor Michael Dustin

Professor of Immunology and Wellcome Principal Research Fellow, Director of Research of the Kennedy Institute

Dr Nicholas McGranahan

Group Leader in Cancer Genomics Bioinformatics and Somatic Evolution, CRUK-UCL Lung Centre of Excellence

Dr Martin Miller

Group Leader in Cancer Systems Biology, Cancer Research UK Cambridge Institute

Dr Jurgen Schmitz

Head of Research & Development, Miltenyi Biotec

Professor Len Seymour

Professor of Gene Therapies, University of Oxford

Dr Peter Van Loo

Winton Group Leader in Cancer Genomics, The Francis Crick Institute

Professor Chris Yau

Professor of Artificial Intelligence, University of Manchester and Fellow, The Alan Turing Institute

